Date-Rape Prevention Drug bill

Hillory J. Farias Date-Rape Prevention Drug Act of 1999 - Amends the Controlled Substances Act (CSA) to add gamma hydroxybutyric acid (GHB) to schedule I, ketamine to schedule III, and gamma butyrolactone (GBL) as an additional list I chemical. Provides for a limited exemption from Schedule I manufacturing and distributing facility security requirements for facilities manufacturing and distributing GHB for a Food and Drug Administration (FDA)-approved clinical study, pursuant to the Federal Food, Drug, and Cosmetic Act, in which case Schedule III facility security requirements apply. Places an FDA-approved GHB drug product into Schedule III. Adds Schedule I penalties for the unlawful use of an approved drug product that contains GHB. Specifies that the designation of GBL or any other chemical as a listed chemical under the CSA does not preclude a finding that the chemical is a controlled substance analogue. Includes controlled substance analogues within the scope of provision regarding penalties for distribution of a controlled substance. (Sec. 4) Amends the CSA to authorize the Attorney General to establish specified reporting requirements for GHB products in Schedule III, including annual reports of end-of-year inventories and requirements that dispensing practitioners maintain certain records regarding prescriptions. (Sec. 5) Directs the Attorney General to make a grant for the development of forensic field tests to assist law enforcement officials in detecting the presence of GHB and related substances. (Sec. 6) Directs the Secretary of Health and Human Services to submit to Congress annual reports providing an estimate of the number of incidents of the abuse of date-rape drugs that occurred during the most recent one-year period for which data are available. Requires the Secretary to develop a plan for carrying out a national campaign to educate young adults, youths, law enforcement personnel, educators, school nurses, counselors of rape victims, and hospital emergency room personnel on: (1) the dangers of the date-rape drugs; (2) the applicability of the CSA to such drugs, including penalties; (3) recognizing symptoms indicating that an individual may be a victim of such drugs, including symptoms of sexual assault; and (4) appropriately responding when an individual has such symptoms. Directs the Secretary to establish an advisory committee to make recommendations to the Secretary regarding the plan. Sets forth provisions regarding plan implementation and evaluation.